UBS Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Michael Yee from UBS maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $545.00. The company’s shares closed yesterday at $460.87.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Yee covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Eli Lilly & Co, and SAB Biotherapeutics. According to TipRanks, Yee has an average return of -0.3% and a 42.83% success rate on recommended stocks.
In addition to UBS, Vertex Pharmaceuticals also received a Buy from Citi’s Geoff Meacham in a report issued today. However, on the same day, Needham maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.23 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $2.91 billion and had a net profit of $913 million
Read More on VRTX:
Disclaimer & DisclosureReport an Issue
- Vertex Pharmaceuticals price target raised to $598 from $571 at BofA
- Compelling Buy Thesis on Vertex: Strong IgAN Pivotal Data, Clean Safety, and Robust Peak Sales Potential Support Large-Cap Biotech Upside
- Vertex Pharmaceuticals price target raised to $596 from $570 at Morgan Stanley
- Vertex Pharmaceuticals price target raised to $585 from $575 at Citi
- Vertex Pharmaceuticals initiated with a Buy at Jefferies
